lawsuits against glp 1 Drugs like Ozempic and Wegovy have skyrocketed in popularity for weight loss, but many users have suffered serious, life-altering side effects. Recent claim that Novo Nordisk, the manufacturer, failed to warn GLP-1 Litigation and the Road

Product developers should focus on formulations centred on protein, fibre, resistant starch and healthy fats to capture this demand for evidence-backed, metabolic-health solutions

Present their membership card at the time of prescription purchase

For example, those who are candidates for Wegovy meet the FDA requirements of having a BMI (body mass index) of 30 or more or 27 or more with a weight-related complication, such as hypertension or [high cholesterol], says Tom Wadden, Ph.D., a psychologist and professor at University of Pennsylvania, in Philadelphia, who studies obesity treatments

Eli Lillys tirzepatide (Mounjaro and Zepbound) is a GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 dual agonist that is demonstrating excellent weight loss, type 2 diabetes management, as well as cardiovascular protection

Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes and chronic weight management